Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small glycanic drugs - Endotis

Drug Profile

Research programme: small glycanic drugs - Endotis

Alternative Names: EP 30; EP 31; EP 32; EP 33; EP 80061; EP8000; Small glycanic drugs research programme - Endotis

Latest Information Update: 03 Oct 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endotis Pharma
  • Class Oligosaccharides
  • Mechanism of Action Chemokine receptor antagonists; Intercellular signalling peptide and protein inhibitors; Interferon gamma inhibitors; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 02 Mar 2011 Preclinical development in Solid tumours is ongoing in France
  • 01 Jan 2011 Preclinical trials in Cancer in France (Parenteral)
  • 17 Apr 2010 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top